Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Monoboosted lopinavir/ritonavir as simplified second-line maintenance therapy in virologically suppressed children.

Bunupuradah T, Kosalaraksa P, Puthanakit T, Mengthaisong T, Wongsabut J, Lumbiganon P, Phanuphak P, Burger D, Pancharoen C, Ananworanich J; HIV-NAT 077 Study Team.

AIDS. 2011 Jan 28;25(3):315-23. doi: 10.1097/QAD.0b013e32834231f5.

PMID:
21157298
2.

Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir.

Gutmann C, Cusini A, Günthard HF, Fux C, Hirschel B, Decosterd LA, Cavassini M, Yerly S, Vernazza PL; Swiss HIV Cohort Study (SHCS).

AIDS. 2010 Sep 24;24(15):2347-54. doi: 10.1097/QAD.0b013e32833db9a1.

PMID:
20802298
3.

Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.

Neth O, Falcon-Neyra L, Ruiz-Valderas R, León Leal JA, Obando I, Alvarez Del Vayo Benito C, Lopez-Cortes LF.

Pediatr Infect Dis J. 2011 Oct;30(10):917. doi: 10.1097/INF.0b013e318223bc56. No abstract available.

PMID:
21915022
4.

Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections.

Tan D, Walmsley S.

Expert Rev Anti Infect Ther. 2007 Feb;5(1):13-28. Review.

PMID:
17266450
5.

[From HAART to "smart": maximizing the advantages of lopinavir/ritonavir].

[No authors listed]

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:68-9. German. No abstract available.

PMID:
15373055
6.

Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.

Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.

J Antimicrob Chemother. 2008 Jan;61(1):183-90. Epub 2007 Nov 19.

7.

Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.

Voigt E, Wasmuth JC, Vogel M, Mauss S, Schmutz G, Kaiser R, Rockstroh JK.

Infection. 2004 Apr;32(2):82-8.

PMID:
15057572
8.

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M; OK04 Study Group.

AIDS. 2008 Jan 11;22(2):F1-9.

PMID:
18097218
9.

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

L'homme RF, Nijland HM, Gras L, Aarnoutse RE, van Crevel R, Boeree M, Brinkman K, Prins JM, Juttmann JR, Burger DM.

AIDS. 2009 Apr 27;23(7):863-5. doi: 10.1097/QAD.0b013e328329148e.

PMID:
19352137
10.

Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.

Luis Jiménez J, Resino S, Martinez-Colom A, Bellón JM, Angeles Muñoz-Fernández M; Spanish Group of Paediatric HIV Infection.

J Antimicrob Chemother. 2005 Dec;56(6):1081-6. Epub 2005 Sep 29.

11.

Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks.

Bunupuradah T, van der Lugt J, Kosalaraksa P, Engchanil C, Boonrak P, Puthanakit T, Mengthaisong T, Mahanontharit A, Lumbiganon P, Tompkins E, Burger D, Ruxrungtham K, Ananworanich J; HIV-NAT 017 Study Team.

Antivir Ther. 2009;14(2):241-8.

PMID:
19430099
12.

Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice.

Prosperi MC, Zazzi M, Punzi G, Monno L, Colao G, Corsi P, Di Giambenedetto S, Meini G, Ghisetti V, Bonora S, Pecorari M, Gismondo MR, Bagnarelli P, Carli T, De Luca A; ARCA Collaborative Group.

J Med Virol. 2010 Dec;82(12):1996-2003. doi: 10.1002/jmv.21927.

PMID:
20981785
13.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.

J Antimicrob Chemother. 2008 Jan;61(1):200-5. Epub 2007 Nov 13.

14.

Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.

Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, Phanuphak P, Chaithongwongwatthana S, Avihingsanon A, Phanuphak N.

AIDS. 2011 Jun 19;25(10):1299-303. doi: 10.1097/QAD.0b013e328347f7e9.

PMID:
21516029
15.

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.

Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF.

Antivir Ther. 2010;15(7):993-1002. doi: 10.3851/IMP1666.

PMID:
21041914
16.

Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.

Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM; Puzzle 1 Study Group.

Antivir Ther. 2004 Aug;9(4):615-25.

PMID:
15456093
17.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

18.

Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.

Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF; MONARK Study Group.

HIV Med. 2010 Feb;11(2):137-42. doi: 10.1111/j.1468-1293.2009.00752.x. Epub 2009 Aug 13.

19.

Lopinavir/ritonavir: appraisal of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2007 Apr;43(4):221-47. Review.

PMID:
17460785
20.

Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.

Bongiovanni M, Chiesa E, Di Biagio A, Meraviglia P, Capetti A, Tordato F, Cicconi P, Biasi P, Bini T, d'Arminio Monforte A.

J Antimicrob Chemother. 2005 Jun;55(6):1003-7. Epub 2005 Apr 11.

Items per page

Supplemental Content

Write to the Help Desk